392 related articles for article (PubMed ID: 25967123)
21. Fibroblast Growth Factor-23-A Potential Uremic Toxin.
Kuczera P; Adamczak M; Wiecek A
Toxins (Basel); 2016 Dec; 8(12):. PubMed ID: 27941640
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.
Kovesdy CP; Quarles LD
Nephrol Dial Transplant; 2013 Sep; 28(9):2228-36. PubMed ID: 23625971
[TBL] [Abstract][Full Text] [Related]
23. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
[TBL] [Abstract][Full Text] [Related]
24. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
[TBL] [Abstract][Full Text] [Related]
25. Inflammation regulates fibroblast growth factor 23 production.
Francis C; David V
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):325-32. PubMed ID: 27191351
[TBL] [Abstract][Full Text] [Related]
26. The role of bone in CKD-mediated mineral and vascular disease.
Khouzam NM; Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2015 Sep; 30(9):1379-88. PubMed ID: 25168424
[TBL] [Abstract][Full Text] [Related]
27. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
Grabner A; Faul C
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
[TBL] [Abstract][Full Text] [Related]
28. Fibroblast growth factor 23/klotho axis in chronic kidney disease.
Nitta K; Nagano N; Tsuchiya K
Nephron Clin Pract; 2014; 128(1-2):1-10. PubMed ID: 25402964
[TBL] [Abstract][Full Text] [Related]
29. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.
Ketteler M; Biggar PH; Liangos O
Nephrol Dial Transplant; 2013 Apr; 28(4):821-5. PubMed ID: 23233522
[TBL] [Abstract][Full Text] [Related]
30. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
Hasegawa H; Nagano N; Urakawa I; Yamazaki Y; Iijima K; Fujita T; Yamashita T; Fukumoto S; Shimada T
Kidney Int; 2010 Nov; 78(10):975-80. PubMed ID: 20844473
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Koizumi M; Komaba H; Fukagawa M
Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
[TBL] [Abstract][Full Text] [Related]
32. [Phosphate metabolism and iron deficiency].
Yokoyama K
Clin Calcium; 2016 Feb; 26(2):241-9. PubMed ID: 26813504
[TBL] [Abstract][Full Text] [Related]
33. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
[TBL] [Abstract][Full Text] [Related]
34. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
Spatz C; Roe K; Lehman E; Verma N
Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
[TBL] [Abstract][Full Text] [Related]
35. Phosphate homeostasis, parathyroid hormone, and fibroblast growth factor 23 in stages 3 and 4 chronic kidney disease.
Phelps KR; Mason DL; Stote KS
Clin Nephrol; 2016 May; 85(5):251-61. PubMed ID: 26951967
[TBL] [Abstract][Full Text] [Related]
36. Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No' at the moment, but stay tuned.
Zoccali C; Mallamaci F
Nephrol Dial Transplant; 2016 Feb; 31(2):196-9. PubMed ID: 26681749
[TBL] [Abstract][Full Text] [Related]
37. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.
Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T
Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314
[TBL] [Abstract][Full Text] [Related]
38. Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT).
Adema AY; de Jong MA; de Borst MH; Ter Wee PM; Vervloet MG;
Nephron; 2016; 134(4):215-220. PubMed ID: 27442253
[TBL] [Abstract][Full Text] [Related]
39. Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.
Agoro R; White KE
Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):320-325. PubMed ID: 35703246
[TBL] [Abstract][Full Text] [Related]
40. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
